SOURCE: PharmStar Pharmaceuticals, Inc.

May 25, 2011 10:23 ET

PharmStar Pharmaceuticals Addresses Bayer Aspirin Reformulation

WILSON, NC--(Marketwire - May 25, 2011) - PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today published the following statements in response to the recent announcement (May 23, 2011) from Bayer AG regarding its new product, "Bayer Advanced Aspirin."

PharmStar management stated that it believes Aquaprin, the signature product from PharmStar Pharmaceuticals, Inc., will be the fastest acting analgesic on the market.

Bayer introduced a reformulation of its tablet earlier this week, and the research is telling. Bayer has created a tablet that now begins working in 16 minutes, and reaches "meaningful pain relief" in 49 minutes. Compare that to Aquaprin, a liquid derivative of aspirin, which begins working in less than 3 minutes, and eases a headache in less than 10 minutes. Aquaprin is also non-acidic, acts as an antacid, and is easy on the stomach -- unmatched by any aspirin tablet on the market.

PharmStar CEO Howard Phykitt stated, "We have always known tablets take too much time to start working. It is the nature of tablet forms of medicine, and is the reason that I developed Aquaprin and related line extension products. Improving the therapeutic effectiveness to 49 minutes is a good start, but Aquaprin reaches that level in less than 10 minutes. Not to mention this new Bayer aspirin is still acidic, only delivering about 45-50% of the medicine into the bloodstream. Aquaprin is not acidic, but is an antacid, and delivers 100% of the medicine. So, reducing the time that you have to endure a headache from 100 minutes down to 49 minutes is good news I guess, but it means little to those that can't let an acidic tablet sit on their stomach even that long."

Mr. Phykitt continued, "This announcement by Bayer is a clear signal that the analgesic market is now more demanding and one that can be supplied with faster pain relief products. By Bayer's own admission, its product is now better known for preventing heart attacks than as a pain reliever. I believe Bayer is trying to remind consumers its aspirin also works well for killing pain, and that its new product works more quickly than its standard aspirin."

"I am happy that Bayer is re-educating people about the value of aspirin as a pain reliever, as it has been valuable for thousands of years," concluded Mr. Phykitt. "Wait until those same people experience aspirin at its best, when our liquid derivative hits the market. We are not doing the same thing over and over, but really advancing the great value of aspirin to a superior level."

About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Wilson, NC. For more information, visit

Forward-Looking Statements Disclosure
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "will," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Contact Information